Renal Masses—To Treat or Not to Treat? If That is the Question are Contemporary Biomarkers the Answer?
Author:
- 1 August 2008
- journal article
- editorial
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 180 (2) , 433-434
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Predicting disease progression after nephrectomy for localized renal cell carcinoma: The utility of prognostic models and molecular biomarkersCancer, 2008
- Excise, Ablate or Observe: The Small Renal Mass Dilemma—A Meta-Analysis and ReviewJournal of Urology, 2008
- Delayed intervention of sporadic renal masses undergoing active surveillanceCancer, 2008
- Enhancing Renal Masses With Zero Net Growth During Active SurveillanceJournal of Urology, 2007
- The Natural History of Observed Enhancing Renal Masses: Meta-Analysis and Review of the World LiteratureJournal of Urology, 2006
- Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell CancerNew England Journal of Medicine, 2001
- Evidence based medicine: what it is and what it isn'tBMJ, 1996